We explore 7 key trends that we think will shape the oncology market in 2026 and beyond:

  1. New IO backbones built around 1.) PD-(L)1×VEGF, 2.) checkpoint-plus bispecifics, and 3.) early solid-tumor cell therapy 2.0
  2. Antibody-Drug Conjugate (ADC) 2.0 platforms that differentiate on targets, linkers, manufacturability, and combination strategy
  3. Radiopharmaceuticals moving earlier in treatment and entering a true combination and “alpha era”
  4. Diagnostics evolving from standalone tests into care-delivery products, with circulating tumor DNA Minimal Residual Disease (ctDNA-MRD) and multi-cancer early detection (MCED) at the core
  5. Patient “ownership” and care delivery becoming a bottleneck as complex therapies expand beyond traditional oncology settings
  6. The cross-cutting role for artificial intelligence (AI) in oncology, as it moves from pilots to infrastructure and touches everything from trial design and imaging to diagnostics, sourcing, and patient navigation
  7. China-to-global sourcing models that are resetting expectations on speed, pricing, and execution under growing policy scrutiny